Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome

Cerrillo, M.; Pacheco, A.; Rodrı́guez, Sara; Gómez, Raúl; Delgado, Francisco; Pellicer, António; Garcia-Velasco, Juan A.

doi:10.1016/j.fertnstert.2010.12.054

Cited by 54 publications

(49 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we did not show any significant differences in lutealphase VEGF levels between patients triggered with either GnRH agonist or hCG. These findings are consistent with those of other studies that did not find any significant differences in luteal-phase serum or plasma VEGF levels (1,7,17) and may be related to methodologic issues with the VEGF analysis (23).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Engmann

Romak

Nulsen

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

“…In fact, previous studies have shown that GnRH agonist trigger results in significantly lower VEGF levels in follicular fluid (7,17) and in mRNA expression in granulosa cells (17). However, the present study did not show any differences in the follicular-fluid VEGF concentrations after GnRH agonist or hCG trigger.…”

Section: Discussioncontrasting

confidence: 91%

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Engmann

Romak

Nulsen

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

“…The cryopreservation of all embryos can prevent pregnancy-induced late OHSS; however, it cannot prevent early OHSS if hCG is used to trigger oocyte maturation (Endo et al, 2002) The use of gonadotropin-releasing hormone agonist (GnRHa) as a trigger for final oocyte maturation in antagonist in vitro fertilization (IVF) cycles has been proposed as a method for preventing ovarian OHSS (Cerrillo et al, 2011;Humaidan et al, 2011). From a clinical point of view, the most significant benefit of GnRHa trigger is its ability to induce a quick and reversible luteolysis and thus reduce the risk of OHSS development.…”

Section: Introductionmentioning

confidence: 99%

Strategies for the management of OHSS: Results from freezing-all cycles

Borges¹,

Braga²,

Setti³

et al. 2016

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: To compare the use of GnRH agonist (GnRHa) or hCG trigger in potential OHSS patients undergoing freeze-all programs. We also compared the clinical outcomes when fresh versus freeze-thawed embryo transfers were performed in cycles with a high number of retrieved oocytes. Methods: The study included potential OHSS patients who received GnRHa (n=74) or hCG (n=49) trigger. The protocols were compared with respect to the clinical outcomes. We also compared the clinical outcomes of cycles in which hCG trigger was used and more than 20 MII oocytes were retrieved when: fresh embryo transfer protocol (n=153) or freeze-all protocol (n=123) were performed. Results: A decreased serum estradiol level, a decreased number of retrieved oocytes, an increased MII retrieved rate, and decreased fertilization rate was observed in the hCG when compared with the GnRHa group. No significant differences were noted concerning clinical outcomes. When fresh cycles were compared with frozen-thawed cycles, the estradiol serum level and the number of cryopreserved embryos were higher in the frozen-thawed cycles. The clinical pregnancy rate was higher among freeze-all cycles, as well as the implantation and cumulative pregnancy rates, when compared with fresh embryo transfer cycles. Conclusion:The use of GnRHa trigger may be a good alternative to prevent the OHSS in patients presenting an extreme ovarian response to COS, leading to similar clinical outcomes, when compared with the traditional hCG trigger. Moreover, our findings demonstrated that the strategy of freezing-all embryos not only decreases the risk of OHSS but also leads to a better pregnancy rate.

show abstract

“…High levels of HCG are felt to cause an over expression of vascular endothelial growth factor in the developing follicles leading to a release of vasoactive substances [13,14]. The result is ovarian enlargement as well as capillary hyperpermeability with fluid extravasation causing ascites, pleural and pericardial effusions.…”

Section: Pathophysiology Of Ohssmentioning

confidence: 99%

A Brief Review of Stroke associated with Assisted Reproductive Technology

O’Neal¹

2017

J Neurol Neurophysiol

View full text Add to dashboard Cite

Strokes related to assisted reproductive technology are rare, but can be devastating. In order to understand how stroke can occur as a complication of assisted reproductive technology, both the normal physiology of ovulation and the hormonal manipulations used to maximize pregnancy will be examined. In particular, the danger of thrombotic complications related to ovarian hyperstimulation syndrome will be reviewed including the pathophysiology, clinical features, risk factors and treatment.

show abstract

Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome

Cited by 54 publications

References 19 publications

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Strategies for the management of OHSS: Results from freezing-all cycles

A Brief Review of Stroke associated with Assisted Reproductive Technology

Contact Info

Product

Resources

About